Antibody
Showing 1 - 25 of >10,000
Antineutrophil Cytoplasmic Antibody-associated Vasculitis Trial (Avacopan, Placebo, Standard of Care)
Not yet recruiting
- Antineutrophil Cytoplasmic Antibody-associated Vasculitis
- Avacopan
- +2 more
- (no location specified)
Oct 6, 2023
Advanced Solid Tumors Trial in Guangzhou (MR001)
Not yet recruiting
- Advanced Solid Tumors
-
Guangzhou, Guangdong, ChinaNanfang Hospital, Southern Medical University
Nov 12, 2023
Antibody-mediated Rejection, Kidney Tranplant Trial in Hangzhou (Daratumumab)
Not yet recruiting
- Antibody-mediated Rejection
- Kidney Tranplant
-
Hangzhou, Zhejiang, China79# Qingchun Road
Jun 21, 2023
Evan Syndrome, Treatment Trial in Tianjin (Anti-CD38 antibody Injection)
Recruiting
- Evan Syndrome
- Treatment
- Anti-CD38 antibody Injection
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Aug 25, 2023
Bevacizumab Combined With PD-1 Monoclonal Antibody in
Not yet recruiting
- Colorectal Cancer
- Bevacizumab Combined With PD-1 Monoclonal Antibody
- (no location specified)
Nov 8, 2023
SARS-CoV-2, Prevention Trial in Chongqing (A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray, A8G6 SARS-CoV-2
Recruiting
- SARS-CoV-2
- Prevention
- A8G6 SARS-CoV-2 Neutralization Antibody combination nasal spray
- A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient
-
Chongqing, Chongqing, ChinaThe Second Affiliated Hospital of Chongqing Medical University
Nov 9, 2023
Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)
Recruiting
- Safety and Efficacy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 27, 2023
Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)
Not yet recruiting
- Stage IIIA Hepatocellular Carcinoma
- Radiotherapy combined with TKI and Anti-PD-1 Antibody
- (no location specified)
Sep 24, 2023
Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)
Not yet recruiting
- Rectal Cancer
- Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
- (no location specified)
Aug 29, 2023
Antiphospholipid Syndrome, Thrombocytopenia Trial in Tianjin (Anti-CD38 antibody Injection)
Recruiting
- Antiphospholipid Syndrome
- Thrombocytopenia
- Anti-CD38 antibody Injection
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023
The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT Trial (CD25
Not yet recruiting
- The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
- CD25 prophylaxis
- (no location specified)
Jun 20, 2023
Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1
Active, not recruiting
- Gastric or Gastroesophageal Junction Adenocarcinoma
- neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Jul 4, 2023
SARS-CoV-2, Prevention Trial in Chongqing (MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray, Placebo Comparator: MY-586
Recruiting
- SARS-CoV-2
- Prevention
- MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray
- Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient
-
Chongqing, Chongqing, ChinaThe Second Affiliated Hospital of Chongqing Medical University
Aug 2, 2023
Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Refractory Non-Small Cell Lung Cancer
- Daratumumab
- +2 more
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023
Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)
Recruiting
- Biliary Tract Cancer
- +2 more
-
Shanghai, ChinaZhongshan hospital, Fudan University
Aug 12, 2023
COVID-19 Trial in Beijing (SA55 nasal spray)
Recruiting
- COVID-19
- SA55 nasal spray
-
Beijing, Chaoyang, ChinaBeijing Ditan Hospital Capital Medical University
Sep 15, 2023
Assess New Participant's Perspectives Beyond Clinical Efficacy
Not yet recruiting
- Multiple Sclerosis, Relapsing-Remitting
- (no location specified)
Nov 7, 2023
Subclass of Donor-specific Antibody asRisk Factor of Antibody
Active, not recruiting
- Antibody-mediated Rejection
-
Montpellier, Hérault, FranceCHU Lapeyronie
Jan 18, 2023
Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant
Not yet recruiting
- Multiple Cancer
- Colorectal Cancer
- MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
- All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
- (no location specified)
Aug 20, 2023
PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)
Not yet recruiting
- PD-1 Antibody
- +3 more
- L-DEP and PD-1 antibody
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Mar 8, 2023
Syphilis Infection, Syphilis, Early Syphilis, Symptomatic Trial (Reveal TP (Syphilis) Antibody Test)
Not yet recruiting
- Syphilis Infection
- +2 more
- Reveal TP (Syphilis) Antibody Test
- (no location specified)
Apr 14, 2023
MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)
Not yet recruiting
- MSS
- Rectal Cancer
- Sintilimab with Interleukin-2
- (no location specified)
Nov 1, 2023
SARS-CoV2 Infection Trial in Flint (General SARS-CoV-2 Communication, Rural-Targeted SARS-CoV-2 Communication)
Recruiting
- SARS-CoV2 Infection
- General SARS-CoV-2 Communication
- Rural-Targeted SARS-CoV-2 Communication
-
Flint, MichiganFlint Journal Building
Oct 10, 2023